A Phase 3 Extension Study to Assess the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Condition:   Endometriosis Interventions:   Drug: 75 mg linzagolix tablet;   Drug: 200 mg linzagolix tablet;   Drug: Placebo tablet to match 75 mg linzagolix tablet;   Drug: Placebo tablet to match 200 mg linzagolix tablet;   Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg);   Drug: Placebo capsule to match Add-ba ck capsule Sponsor:   ObsEva SA Enrolling by invitation

Source: ClinicalTrials.gov - April 6, 2020 Category: Research Source Type: clinical trials